These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 27562370)

  • 1. Site-specific Isopeptide Bridge Tethering of Chimeric gp41 N-terminal Heptad Repeat Helical Trimers for the Treatment of HIV-1 Infection.
    Wang C; Li X; Yu F; Lu L; Jiang X; Xu X; Wang H; Lai W; Zhang T; Zhang Z; Ye L; Jiang S; Liu K
    Sci Rep; 2016 Aug; 6():32161. PubMed ID: 27562370
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Suitable fusion of N-terminal heptad repeats to achieve covalently stabilized potent N-peptide inhibitors of HIV-1 infection.
    Lai W; Wang C; Yan J; Liu H; Zhang W; Lin B; Xi Z
    Bioorg Med Chem; 2020 Feb; 28(4):115214. PubMed ID: 31932193
    [TBL] [Abstract][Full Text] [Related]  

  • 3.
    Wang C; Lai W; Yu F; Zhang T; Lu L; Jiang X; Zhang Z; Xu X; Bai Y; Jiang S; Liu K
    Chem Sci; 2015 Nov; 6(11):6505-6509. PubMed ID: 30090269
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Covalent stabilization of coiled coils of the HIV gp41 N region yields extremely potent and broad inhibitors of viral infection.
    Bianchi E; Finotto M; Ingallinella P; Hrin R; Carella AV; Hou XS; Schleif WA; Miller MD; Geleziunas R; Pessi A
    Proc Natl Acad Sci U S A; 2005 Sep; 102(36):12903-8. PubMed ID: 16129831
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Probing Vulnerability of the gp41 C-Terminal Heptad Repeat as Target for Miniprotein HIV Inhibitors.
    Jurado S; Moog C; Cano-Muñoz M; Schmidt S; Laumond G; Ruocco V; Standoli S; Polo-Megías D; Conejero-Lara F; Morel B
    J Mol Biol; 2020 Sep; 432(20):5577-5592. PubMed ID: 32822695
    [TBL] [Abstract][Full Text] [Related]  

  • 6. An effective strategy for recapitulating N-terminal heptad repeat trimers in enveloped virus surface glycoproteins for therapeutic applications.
    Lai W; Wang C; Yu F; Lu L; Wang Q; Jiang X; Xu X; Zhang T; Wu S; Zheng X; Zhang Z; Dong F; Jiang S; Liu K
    Chem Sci; 2016 Mar; 7(3):2145-2150. PubMed ID: 29899942
    [TBL] [Abstract][Full Text] [Related]  

  • 7. An engineered HIV-1 gp41 trimeric coiled coil with increased stability and anti-HIV-1 activity: implication for developing anti-HIV microbicides.
    Tong P; Lu Z; Chen X; Wang Q; Yu F; Zou P; Yu X; Li Y; Lu L; Chen YH; Jiang S
    J Antimicrob Chemother; 2013 Nov; 68(11):2533-44. PubMed ID: 23794600
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Hydrophobic mutations in buried polar residues enhance HIV-1 gp41 N-terminal heptad repeat-C-terminal heptad repeat interactions and C-peptides' anti-HIV activity.
    Zheng B; Wang K; Lu L; Yu F; Cheng M; Jiang S; Liu K; Cai L
    AIDS; 2014 Jun; 28(9):1251-60. PubMed ID: 24625369
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Novel recombinant engineered gp41 N-terminal heptad repeat trimers and their potential as anti-HIV-1 therapeutics or microbicides.
    Chen X; Lu L; Qi Z; Lu H; Wang J; Yu X; Chen Y; Jiang S
    J Biol Chem; 2010 Aug; 285(33):25506-15. PubMed ID: 20538590
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Broad antiviral activity and crystal structure of HIV-1 fusion inhibitor sifuvirtide.
    Yao X; Chong H; Zhang C; Waltersperger S; Wang M; Cui S; He Y
    J Biol Chem; 2012 Feb; 287(9):6788-96. PubMed ID: 22228771
    [TBL] [Abstract][Full Text] [Related]  

  • 11. ADS-J1 inhibits HIV-1 infection and membrane fusion by targeting the highly conserved pocket in the gp41 NHR-trimer.
    Yu F; Lu L; Liu Q; Yu X; Wang L; He E; Zou P; Du L; Sanders RW; Liu S; Jiang S
    Biochim Biophys Acta; 2014 May; 1838(5):1296-305. PubMed ID: 24388952
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Trimeric heptad repeat synthetic peptides HR1 and HR2 efficiently inhibit HIV-1 entry.
    Mzoughi O; Teixido M; Planès R; Serrero M; Hamimed I; Zurita E; Moreno M; Granados G; Lakhdar-Ghazal F; BenMohamed L; Giralt E; Bahraoui E
    Biosci Rep; 2019 Sep; 39(9):. PubMed ID: 31477581
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A salt bridge between an N-terminal coiled coil of gp41 and an antiviral agent targeted to the gp41 core is important for anti-HIV-1 activity.
    Jiang S; Debnath AK
    Biochem Biophys Res Commun; 2000 Apr; 270(1):153-7. PubMed ID: 10733920
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A novel bispecific peptide HIV-1 fusion inhibitor targeting the N-terminal heptad repeat and fusion peptide domains in gp41.
    Jiang X; Jia Q; Lu L; Yu F; Zheng J; Shi W; Cai L; Jiang S; Liu K
    Amino Acids; 2016 Dec; 48(12):2867-2873. PubMed ID: 27631437
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Supercoiling Structure-Based Design of a Trimeric Coiled-Coil Peptide with High Potency against HIV-1 and Human β-Coronavirus Infection.
    Wang C; Xia S; Wang X; Li Y; Wang H; Xiang R; Jiang Q; Lan Q; Liang R; Li Q; Huo S; Lu L; Wang Q; Yu F; Liu K; Jiang S
    J Med Chem; 2022 Feb; 65(4):2809-2819. PubMed ID: 33929200
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Short communication: In vitro synergy between peptides or neutralizing antibodies targeting the N- and C-terminal heptad repeats of HIV Type 1 gp41.
    Hrin R; Montgomery DL; Wang F; Condra JH; An Z; Strohl WR; Bianchi E; Pessi A; Joyce JG; Wang YJ
    AIDS Res Hum Retroviruses; 2008 Dec; 24(12):1537-44. PubMed ID: 19102685
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Differential inhibition of HIV-1 and SIV envelope-mediated cell fusion by C34 peptides derived from the C-terminal heptad repeat of gp41 from diverse strains of HIV-1, HIV-2, and SIV.
    Gustchina E; Hummer G; Bewley CA; Clore GM
    J Med Chem; 2005 Apr; 48(8):3036-44. PubMed ID: 15828842
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Development of HIV entry inhibitors targeted to the coiled-coil regions of gp41.
    Jiang S; Debnath AK
    Biochem Biophys Res Commun; 2000 Mar; 269(3):641-6. PubMed ID: 10720469
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Membrane-anchored inhibitory peptides capture human immunodeficiency virus type 1 gp41 conformations that engage the target membrane prior to fusion.
    Melikyan GB; Egelhofer M; von Laer D
    J Virol; 2006 Apr; 80(7):3249-58. PubMed ID: 16537592
    [TBL] [Abstract][Full Text] [Related]  

  • 20. HIV-1 variants with a single-point mutation in the gp41 pocket region exhibiting different susceptibility to HIV fusion inhibitors with pocket- or membrane-binding domain.
    Lu L; Tong P; Yu X; Pan C; Zou P; Chen YH; Jiang S
    Biochim Biophys Acta; 2012 Dec; 1818(12):2950-7. PubMed ID: 22867851
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.